Function of miR‑152 as tumor suppressor in oral squamous cell carcinoma cells by targeting c‑MET Retraction in /10.3892/or.2022.8254

Li,Minghe; Li,Zhihong; Wang,Xue; Wang,Yumei; Zhao,Cong; Wang,Lei

doi:10.3892/or.2017.6157

Function of miR‑152 as tumor suppressor in oral squamous cell carcinoma cells by targeting c‑MET

Retraction in: /10.3892/or.2022.8254

Authors:
- Minghe Li
- Zhihong Li
- Xue Wang
- Yumei Wang
- Cong Zhao
- Lei Wang
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Hospital of Stomatology, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Dentistry, The General Hospital of FAW, Changchun, Jilin 1300000, P.R. China, Department of Endodontics, Hospital of Stomatology, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Periodontology, Hospital of Stomatology, Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: December 15, 2017 https://doi.org/10.3892/or.2017.6157
Pages: 1173-1180

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA‑152 (miR‑152) has been reported to be involved in tumor development and progression in multiple cancers. However, the expression level, biological function and regulatory mechanisms of miR‑152 in oral squamous cell carcinoma cells (OSCC) remain unclear. The aims of this study were therefore to investigate the role of miR‑152 in OSCC and the relevant mechanism. It was found that miR‑152 was downregulated in OSCC cell lines and tissues, and that decreased miR‑152 was closely associated with lymph node metastasis, and patient survival rate. In vitro restoration of miR‑152 significantly repressed cell proliferation, colony formation, migration and invasion of OSCC cells. Notably, cellular-mesenchymal to epithelial transition factor (c‑MET) and its downstream signaling pathway (PI3K/AKT) was downregulated in OSCC cells by miR‑152 through direct interactions with its 3' untranslated region. Restoring c‑MET expression attenuated miR‑152-induced inhibitory effects in OSCC cells. In vivo study confirmed that restoration of miR‑152 suppressed tumor growth in xenograft nude mice by repressing c‑MET. In summary, the present study highlight miR‑152 as a tumor suppressor in OSCC through direct targeting c‑MET, rendering miR‑152 a promising therapeutic target for oral squamous cell carcinoma.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Liao CT, Hsueh C, Lee LY, Lin CY, Fan KH, Wang HM, Huang SF, Chen IH, Kang CJ, Ng SH, et al: Neck dissection field and lymph node density predict prognosis in patients with oral cavity cancer and pathological node metastases treated with adjuvant therapy. Oral Oncol. 48:329–336. 2012. View Article : Google Scholar : PubMed/NCBI
3	Jerjes W, Upile T, Petrie A, Riskalla A, Hamdoon Z, Vourvachis M, Karavidas K, Jay A, Sandison A, Thomas GJ, et al: Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients. Head Neck Oncol. 2:92010. View Article : Google Scholar : PubMed/NCBI
4	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
5	Malan-Müller S, Hemmings SM and Seedat S: Big effects of small RNAs: A review of microRNAs in anxiety. Mol Neurobiol. 47:726–739. 2013. View Article : Google Scholar : PubMed/NCBI
6	McManus MT: MicroRNAs and cancer. Semin Cancer Biol. 13:253–258. 2003. View Article : Google Scholar : PubMed/NCBI
7	Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011. View Article : Google Scholar : PubMed/NCBI
8	Garzon R and Marcucci G: Potential of microRNAs for cancer diagnostics, prognostication and therapy. Curr Opin Oncol. 24:655–659. 2012. View Article : Google Scholar : PubMed/NCBI
9	Prasad G, Seers C, Reynolds E and McCullough MJ: A panel of microRNAs can be used to determine oral squamous cell carcinoma. J Oral Pathol Med. 46:940–948. 2017.PubMed/NCBI
10	Ries J, Baran C, Wehrhan F, Weber M, Neukam FW, Krautheim-Zenk A and Nkenke E: Prognostic significance of altered miRNA expression in whole blood of OSCC patients. Oncol Rep. 37:3467–3474. 2017. View Article : Google Scholar : PubMed/NCBI
11	Xie G, Li W, Li R, Wu K, Zhao E, Zhang Y, Zhang P, Shi L, Wang D, Yin Y, et al: Helicobacter pylori promote B7-H1 expression by suppressing miR-152 and miR-200b in gastric cancer cells. PLoS One. 12:e01688222017. View Article : Google Scholar : PubMed/NCBI
12	Li B, Xie Z and Li B: miR-152 functions as a tumor suppressor in colorectal cancer by targeting PIK3R3. Tumour Biol. 37:10075–10084. 2016. View Article : Google Scholar : PubMed/NCBI
13	Chen MJ, Cheng YM, Chen CC, Chen YC and Shen CJ: miR-148a and miR-152 reduce tamoxifen resistance in ER⁺ breast cancer via downregulating ALCAM. Biochem Biophys Res Commun. 483:840–846. 2017. View Article : Google Scholar : PubMed/NCBI
14	Zhang YJ, Liu XC, Du J and Zhang YJ: miR-152 regulates metastases of non-small cell lung cancer cells by targeting neuropilin-1. Int J Clin Exp Pathol. 8:14235–14240. 2015.PubMed/NCBI
15	Tang XL, Lin L, Song LN and Tang XH: Hypoxia-inducible miR-152 suppresses the expression of WNT1 and ERBB3, and inhibits the proliferation of cervical cancer cells. Exp Biol Med (Maywood). 241:1429–1437. 2016. View Article : Google Scholar : PubMed/NCBI
16	Zhu C, Li J, Ding Q, Cheng G, Zhou H, Tao L, Cai H, Li P, Cao Q, Ju X, et al: miR-152 controls migration and invasive potential by targeting TGFα in prostate cancer cell lines. Prostate. 73:1082–1089. 2013. View Article : Google Scholar : PubMed/NCBI
17	Li B, Yang XX, Wang D and Ji HK: MicroRNA-138 inhibits proliferation of cervical cancer cells by targeting c-Met. Eur Rev Med Pharmacol Sci. 20:1109–1114. 2016.PubMed/NCBI
18	Chau L, Jabara JT, Lai W, Svider PF, Warner BM, Lin HS, Raza SN and Fribley AM: Topical agents for oral cancer chemoprevention: A systematic review of the literature. Oral Oncol. 67:153–159. 2017. View Article : Google Scholar : PubMed/NCBI
19	Gharat SA, Momin M and Bhavsar C: Oral squamous cell carcinoma: Current treatment strategies and nanotechnology-based approaches for prevention and therapy. Crit Rev Ther Drug Carrier Syst. 33:363–400. 2016. View Article : Google Scholar : PubMed/NCBI
20	Jasinski-Bergner S, Stoehr C, Bukur J, Massa C, Braun J, Hüttelmaier S, Spath V, Wartenberg R, Legal W, Taubert H, et al: Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma. OncoImmunology. 4:e10088052015. View Article : Google Scholar : PubMed/NCBI
21	Liu DZ, Ander BP, Tian Y, Stamova B, Jickling GC, Davis RR and Sharp FR: Integrated analysis of mRNA and microRNA expression in mature neurons, neural progenitor cells and neuroblastoma cells. Gene. 495:120–127. 2012. View Article : Google Scholar : PubMed/NCBI
22	Huang S, Li X and Zhu H: MicroRNA-152 Targets phosphatase and tensin homolog to inhibit apoptosis and promote cell migration of nasopharyngeal carcinoma cells. Med Sci Monit. 22:4330–4337. 2016. View Article : Google Scholar : PubMed/NCBI
23	Wang Y, Wang D, Xie G, Yin Y, Zhao E, Tao K and Li R: MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma. Oncotarget. 8:28125–28134. 2017.PubMed/NCBI
24	Ge S, Wang D, Kong Q, Gao W and Sun J: Function of miR-152 as a tumor suppressor in human breast cancer by targeting PIK3CA. Oncol Res. 25:1363–1371. 2017. View Article : Google Scholar : PubMed/NCBI
25	Zhou J, Zhang Y, Qi Y, Yu D, Shao Q and Liang J: MicroRNA-152 inhibits tumor cell growth by directly targeting RTKN in hepatocellular carcinoma. Oncol Rep. 37:1227–1234. 2017. View Article : Google Scholar : PubMed/NCBI
26	Skead G and Govender D: Gene of the month: MET. J Clin Pathol. 68:405–409. 2015. View Article : Google Scholar : PubMed/NCBI
27	Marano L, Chiari R, Fabozzi A, De Vita F, Boccardi V, Roviello G, Petrioli R, Marrelli D, Roviello F and Patriti A: c-Met targeting in advanced gastric cancer: An open challenge. Cancer Lett. 365:30–36. 2015. View Article : Google Scholar : PubMed/NCBI
28	Boccaccio C, Luraghi P and Comoglio PM: MET-mediated resistance to EGFR inhibitors: An old liaison rooted in colorectal cancer stem cells. Cancer Res. 74:3647–3651. 2014. View Article : Google Scholar : PubMed/NCBI
29	Ho-Yen CM, Jones JL and Kermorgant S: The clinical and functional significance of c-Met in breast cancer: A review. Breast Cancer Res. 17:522015. View Article : Google Scholar : PubMed/NCBI
30	Mazzone M and Comoglio PM: The Met pathway: Master switch and drug target in cancer progression. FASEB J. 20:1611–1621. 2006. View Article : Google Scholar : PubMed/NCBI
31	Freudlsperger C, Alexander D, Reinert S and Hoffmann J: Prognostic value of c-Met expression in oral squamous cell carcinoma. Exp Ther Med. 1:69–72. 2010.PubMed/NCBI
32	Yasui H, Ohnishi Y, Nakajima M and Nozaki M: Migration of oral squamous cell carcinoma cells are induced by HGF/c-Met signalling via lamellipodia and filopodia formation. Oncol Rep. 37:3674–3680. 2017. View Article : Google Scholar : PubMed/NCBI